You are here: Home » Companies » News
Business Standard

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

Topics
Coronavirus | Pharma Companies | USFDA

Sohini Das  |  Mumbai 

pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory
Under terms of the licensing agreement, these companies will have the right to receive a technology transfer of the Gilead manufacturing process and can scale up production

US-based Gilead Sciences said that it has signed non-exclusive licensing agreements with five generic drug makers in India and Pakistan to expand the supply of antiviral drug remdesivir. The re-purposed Ebola drug is being considered as a potential therapy for (Covid-19).

According to the agreement the Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries. The stocks of and Jubilant were trading high on the BSE in morning trade - Jubilant was up about 5 per cent, 2.5 per cent.

Most of these 127 countries are low-income and lower-middle-income nations along with some upper-middle and high-income countries that face significant obstacles to healthcare access. Under terms of the licensing agreement, these will have the right to receive a technology transfer of the Gilead manufacturing process and can scale up production. This would, however, be subject to approvals by regulatory authorities in the respective countries.

India can also start using the drug on patients on compassionate grounds. The government was checking with on how soon the drug can be manufactured here for trials.

ALSO READ: Covid-19 in numbers: Latest data on cases and deaths in India and globally

Gilead had earlier indicated that it was working to build a global consortium to expand the production of remdesivir and make it available across countries. The drug, which is an injectable, got emergency approval from the US drug regulator recently. The trials show that patients administered with remdesivir recover faster than others. However, remdesivir remains an investigational drug and has not been approved by the

Hetero chairman B Partha Saradhi Reddy said that this agreement illustrates the significance of global collaboration and the need to come together to fight the health crises impacting humanity. "Hetero has developed this product in India and has already been working with the government, ICMR, and DCGI for necessary studies and approvals to bring this product to treat COVID-19 patients in India," he added. It will make remdesivir in its Hyderabad facility which has and EU approvals. Hetero has developed a fully vertically integrated supply chain for this product.

Hetero is one of the largest producers of anti-retroviral drugs.

Similarly, Umang Vohra, MD, and Global CEO, Limited said, “As the world is faced with the COVID-19 crisis, it is imperative that we collaborate and fight this virus together. We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals."


ALSO READ: Covid-19 crisis: Tracking the coronavirus footprint across the world

Jubilant's chairman Shyam S Bhartia and co-chairman Hari S Bhartia felt that based on initial data remdesivir shows promise to be a potential therapy for Covid19. "We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required approvals. We also plan to produce the drug’s active pharmaceutical ingredient (API) in-house, helping its cost-effectiveness and consistent availability," they added.

Gilead is known for getting into licensing agreements with other drugmakers for its patented drugs – it did the same for its hepatitis C drug sofosbuvir earlier. In pandemic situations, India can also invoke its Patents Act and grant compulsory licensing provisions to allow third party manufacturing of a patented drug.

First Published: Wed, May 13 2020. 10:08 IST
RECOMMENDED FOR YOU